Gen-Probe Incorporated (Gen-Probe) has announced that Prodesse’s ProParaflu+ assay has received US Food & Drug (FDA) approval. This assay is a molecular test that detects and differentiates parainfluenza
American Health Packaging has launched additional SKUs in unit-dose line. The SKU’s includes: Ethambutol HCl tablet 400-mg tablets (AB-rated to Myambutol), Rifampin 150mg and 300mg tablets (AB-rated to
American Scientific Resources (ASR) has opened a regional marketing and production management office in Shanghai, China. The company has been able to secure a location abroad, providing an
GW Pharmaceuticals (GW) has completed patient enrollment in its Sativex Phase II/III cancer pain trial. The study is being carried out in collaboration with Otsuka Pharmaceutical (Otsuka), GW’s
Æterna Zentaris has announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial
Addex Pharmaceuticals has announced today that in a non-human primate model of Parkinson’s disease (PD) levodopa induced dyskinesia (LID), ADX48621 inhibited dose dependently both chorea and dystonia, the
France-based Servier has inaugurated a new manufacturing plant. The facility will also act as R&D center for the company. The facility will be based in Arklow, County Wicklow,
PURE Bioscience has entred into an agreement with Charlotte Products, whereby Charlotte Products will blend and package PURE’s patented silver dihydrogen citrate (SDC)-based hard surface disinfectant, which will
Dara BioSciences (Dara) has provided clinical data results for KRN5500, its lead compound for neuropathic pain, which achieved its primary endpoint of pain reduction and demonstrated superior performance
YM BioSciences has reported that Cytopia has commenced enrollment of a Phase I/II trial evaluating Cyt387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is being conducted at Mayo
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.